Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
Key Laboratory of Gastroenterology of Zhejiang Province, Hangzhou 310014, Zhejiang, China.
Cancer Biomark. 2018 Feb 14;21(3):723-730. doi: 10.3233/CBM-170823.
Hypercalcemia is a potentially fatal and not rare complication of hepatocellular carcinoma (HCC), and its underlying mechanism remains unclear. Parathyroid hormone (PTH) is the most important regulator of the concentrations of calcium and phosphate in blood; parathyroid hormone-related protein (PTHrP) was the most frequent cause of humoral hypercalcemia of malignancy; parathyroid hormone 1 receptor (PTH1R) is the common receptor for PTH and PTHrP. The aim of this study is to investigate the expression of PTH, PTHrP, and PTH1R in HCC tissues, and their relationship with clinical pathological characters in HCC.
First, a meta-analysis based on online Oncomine Expression Array database was conducted to compare the different mRNA expression of PTH1R, PTH and PTHrP between hepatocellular carcinoma and normal tissues. Then, the protein expression level of differentially expressed gene was examined by immunohistochemistry staining in 223 HCC tissues and 102 non-tumorous liver tissues controls. The relationship between the protein expression and clinicopathological parameters was analyzed by χ2 test, and overall survival analysis was performed using Kaplan-Meier survival analysis.
PTH1R mRNA expression was significantly lower in HCC tissues compared with normal tissues, while the expression of PTH and PTHrP showed no significant difference between HCC tissues and normal tissues. High PTH1R protein expression was found in 90/102 cases of adjacent non-tumorous liver tissues, and in 91 of 223 cases of HCC tissues. PTH1R expression was significantly related to tumor size, Edmondson Grade, AFP, and overall survival.
PTH1R may be the major cause of hypercalcemia in HCC, and the decreased PTH1R expression was a poor prognosis in HCC.
高钙血症是肝细胞癌(HCC)一种潜在致命且并不罕见的并发症,其潜在机制尚不清楚。甲状旁腺激素(PTH)是调节血液中钙和磷浓度的最重要激素;甲状旁腺激素相关蛋白(PTHrP)是恶性肿瘤引起体液性高钙血症的最常见原因;甲状旁腺激素 1 受体(PTH1R)是 PTH 和 PTHrP 的共同受体。本研究旨在探讨 PTH、PTHrP 和 PTH1R 在 HCC 组织中的表达及其与 HCC 临床病理特征的关系。
首先,通过在线 Oncomine Expression Array 数据库进行荟萃分析,比较肝癌和正常组织中 PTH1R、PTH 和 PTHrP 的不同 mRNA 表达。然后,通过免疫组织化学染色法检测 223 例 HCC 组织和 102 例非肿瘤性肝组织对照中差异表达基因的蛋白表达水平。通过 χ2 检验分析蛋白表达与临床病理参数的关系,采用 Kaplan-Meier 生存分析进行总生存分析。
与正常组织相比,PTH1R mRNA 在 HCC 组织中的表达显著降低,而 PTH 和 PTHrP 在 HCC 组织和正常组织中的表达无显著差异。在 102 例邻近非肿瘤性肝组织中发现 90/102 例存在高 PTH1R 蛋白表达,在 223 例 HCC 组织中发现 91/223 例存在高 PTH1R 蛋白表达。PTH1R 表达与肿瘤大小、Edmondson 分级、AFP 和总生存显著相关。
PTH1R 可能是 HCC 高钙血症的主要原因,PTH1R 表达降低是 HCC 预后不良的因素。